drugset
drugset / Trial / NCT07030959

Study of AUBE00 in Patients With Solid Tumors

NCT07030959 ↗

Phase 1 Recruiting 130 enrolled Chugai Pharmaceutical
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.

Timeline

Start
2025-06-05
Primary completion
2029-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AUBE00 Unknown — Oral
Background Cetuximab Monoclonal antibody — Intravenous

Indications

cancer